These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37141846)

  • 41. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.
    Li J; Wang J; Lei L; Yuan G; He S
    Eur Radiol; 2019 Dec; 29(12):6519-6528. PubMed ID: 31250172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic accuracy of Magnetic Resonance Imaging using liver tissue specific contrast agents and contrast enhanced Multi Detector Computed Tomography: A systematic review of diagnostic test in Hepatocellular Carcinoma (HCC).
    Usman S; Smith L; Brown N; Major V
    Radiography (Lond); 2018 Nov; 24(4):e109-e114. PubMed ID: 30292515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI.
    Brunsing RL; Fowler KJ; Yokoo T; Cunha GM; Sirlin CB; Marks RM
    Hepatoma Res; 2020; 6():. PubMed ID: 33381651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. View-Sharing Artifact Reduction With Retrospective Compressed Sensing Reconstruction in the Context of Contrast-Enhanced Liver MRI for Hepatocellular Carcinoma (HCC) Screening.
    Shaikh J; Stoddard PB; Levine EG; Roh AT; Saranathan M; Chang ST; Muelly MC; Hargreaves BA; Vasanawala SS; Loening AM
    J Magn Reson Imaging; 2019 Apr; 49(4):984-993. PubMed ID: 30390358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool?
    Chan MV; Huo YR; Trieu N; Mitchelle A; George J; He E; Lee AU; Chang J; Yang J
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):44-56.e2. PubMed ID: 33662596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?
    Kurucay M; Kloth C; Kaufmann S; Nikolaou K; Bösmüller H; Horger M; Thaiss WM
    Cancer Imaging; 2017 Jun; 17(1):18. PubMed ID: 28659180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of hemodynamic imaging findings of hypervascular hepatocellular carcinoma: comparison between dynamic contrast-enhanced magnetic resonance imaging using radial volumetric imaging breath-hold examination with k-space-weighted image contrast reconstruction and dynamic computed tomography during hepatic arteriography.
    Kurozumi M; Fujinaga Y; Kitou Y; Yamada A; Ohya A; Adachi Y; Tsukahara Y; Nickel MD; Maruyama K; Uehara T; Miyagawa SI; Kadoya M
    Jpn J Radiol; 2018 Apr; 36(4):295-302. PubMed ID: 29327116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subtraction Images of Gadoxetic Acid-Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma.
    Choi SH; Kim SY; Lee SS; Shim JH; Byun JH; Baek S; Lee MG
    AJR Am J Roentgenol; 2017 Sep; 209(3):584-591. PubMed ID: 28609188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The clinical value of dual-energy computed tomography and diffusion-weighted imaging in the context of liver cancer: A narrative review.
    Fan PL; Chu J; Wang Q; Wang C
    J Clin Ultrasound; 2022 Jul; 50(6):862-868. PubMed ID: 35338779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort.
    Park SH; Kim B; Kim SY; Shim YS; Kim JH; Huh J; Kim HJ; Kim KW; Lee SS
    Eur Radiol; 2020 Apr; 30(4):2302-2311. PubMed ID: 31858203
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
    Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
    Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance.
    Iavarone M; Viganò M; Piazza N; Occhipinti V; Sangiovanni A; Maggioni M; D'Ambrosio G; Forzenigo LV; Motta F; Lampertico P; Rumi MG; Colombo M
    Ann Hepatol; 2019; 18(2):318-324. PubMed ID: 31036496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.
    Park J; Lee JM; Kim TH; Yoon JH
    Clin Mol Hepatol; 2022 Jul; 28(3):362-379. PubMed ID: 34955003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment.
    Jeon SK; Lee DH; Hur BY; Park SJ; Kim SW; Park J; Suh KS; Lee KW; Yi NJ; Han JK
    J Magn Reson Imaging; 2023 Nov; 58(5):1375-1383. PubMed ID: 36825827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.
    Lee SE; An C; Hwang SH; Choi JY; Han K; Kim MJ
    Eur Radiol; 2018 Apr; 28(4):1551-1559. PubMed ID: 29134355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deep learning-assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver.
    Oestmann PM; Wang CJ; Savic LJ; Hamm CA; Stark S; Schobert I; Gebauer B; Schlachter T; Lin M; Weinreb JC; Batra R; Mulligan D; Zhang X; Duncan JS; Chapiro J
    Eur Radiol; 2021 Jul; 31(7):4981-4990. PubMed ID: 33409782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.